Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Imaging Studies III: Computed Tomography01:27

Imaging Studies III: Computed Tomography

251
DefinitionComputed Tomography (CT) of the genitourinary (GU) tract is a non-invasive imaging modality that utilizes X-rays and computer processing to generate detailed cross-sectional images of the urinary system, encompassing the kidneys, ureters, bladder, and adjacent structures such as the adrenal glands.PurposeCT scans of the GU tract serve several diagnostic and therapeutic purposes, including:Diagnosis of Urinary Tract Diseases: Detects kidney stones, tumors, cysts, and congenital...
251
Imaging Studies IV: Magnetic Resonance Imaging01:27

Imaging Studies IV: Magnetic Resonance Imaging

212
Introduction:Magnetic Resonance Imaging, or MRI, can include a specialized imaging technique of the urinary system known as Magnetic Resonance Urography (MRU). This radiation-free technique uses strong magnetic fields and radio waves to produce detailed images with the help of a computer. MRU is particularly effective for visualizing fluid-filled structures like the kidneys, ureters, and bladder.Applications of MRI in the Genitourinary SystemKidneys and Ureters: MRI detects tumors, cysts,...
212
Brain Imaging01:14

Brain Imaging

629
Brain imaging technologies provide critical insights into both the structure and function of the human brain, enabling medical professionals and researchers to diagnose, study, and treat neurological disorders or psychiatric disorders more effectively.
These technologies include computerized axial tomography (CAT or CT scans), positron-emission tomography (PET scans),  magnetic resonance imaging (MRI),  functional magnetic resonance imaging (fMRI), and Transcranial Magnetic...
629
Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

460
Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
460
Imaging Studies I: CT and MRI01:14

Imaging Studies I: CT and MRI

758
Introduction: MRI and CT scans are crucial advancements in medical imaging techniques, playing a vital role in diagnosing conditions related to the gastrointestinal (GI) system. Each scan serves distinct purposes, targets specific areas, and requires unique nursing duties.
Description of the Procedures
Computed Tomography (CT) scan:
Computed Tomography (CT) scans use X-ray technology to generate detailed images of bones, organs, and tissues. During the scan, the patient lies on a moving table...
758

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Multi-domain AD risk burden and plasma biomarkers in cognitively unimpaired adults.

medRxiv : the preprint server for health sciences·2026
Same author

Prior Traumatic Brain Injury and Alzheimer Disease Blood Biomarkers.

JAMA neurology·2026
Same author

Can the All of Us sample be reweighted to mirror a nationally representative sample? A comparison of mortality predictors.

Epidemiology (Cambridge, Mass.)·2026
Same author

Identification of patients receiving amyloid-targeting therapies in observational studies using amyloid PET trajectories: Insights from LEADS.

Alzheimer's & dementia (Amsterdam, Netherlands)·2026
Same author

Improving the clinical trial landscape for patients with atypical variants of Alzheimer's disease: a call to action.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Functional network contributions to longitudinal tau spread in Posterior Cortical Atrophy.

NPJ dementia·2026
Same journal

Evidence for progressive neurodegeneration in iatrogenic cerebral amyloid angiopathy.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Human brain connectome profiles mediate the relationship between pathology burden and clinical phenotypes in Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Kat5 cKO mouse replicates biological domain signatures associated with Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Evaluation of CSF and plasma tau species as fluid surrogate candidates for tau PET in prodromal to moderate Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Associations of self-reported obstructive sleep apnea with cognition and dementia risk in cognitively unimpaired middle-aged adults.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Inflammation profiles in Alzheimer's disease relate to cognition and neurodegeneration.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
関連記事をすべて見る

関連する実験動画

Updated: Jan 8, 2026

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
05:17

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Published on: April 18, 2025

751

アルツハイマー病イメージングコンソーシアム

Sarah F Ackley1, Jason R Gantenberg1, Margo B Heston2

  • 1Brown University, Providence, RI, USA.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 23, 2025
PubMed
まとめ
この要約は機械生成です。

アルツハイマー病(AD)のアミロイド陽電子放出断層撮影(PET)イメージングは、アミロイド蓄積のプラトーの証拠を示さず、既存の時間モデルに疑問を投げかける。高度な定量的ツールを用いたさらなる研究により、ADバイオマーカー進化の理解が深まるだろう。

キーワード:
アルツハイマー病アミロイドPETイメージングバイオマーカー脳神経画像加齢研究モデル

さらに関連する動画

Visualization of Amyloid β Deposits in the Human Brain with Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry
09:31

Visualization of Amyloid β Deposits in the Human Brain with Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry

Published on: March 7, 2019

11.0K
Lesion Explorer: A Video-guided, Standardized Protocol for Accurate and Reliable MRI-derived Volumetrics in Alzheimer's Disease and Normal Elderly
12:50

Lesion Explorer: A Video-guided, Standardized Protocol for Accurate and Reliable MRI-derived Volumetrics in Alzheimer's Disease and Normal Elderly

Published on: April 14, 2014

40.8K

関連する実験動画

Last Updated: Jan 8, 2026

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
05:17

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Published on: April 18, 2025

751
Visualization of Amyloid β Deposits in the Human Brain with Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry
09:31

Visualization of Amyloid β Deposits in the Human Brain with Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry

Published on: March 7, 2019

11.0K
Lesion Explorer: A Video-guided, Standardized Protocol for Accurate and Reliable MRI-derived Volumetrics in Alzheimer's Disease and Normal Elderly
12:50

Lesion Explorer: A Video-guided, Standardized Protocol for Accurate and Reliable MRI-derived Volumetrics in Alzheimer's Disease and Normal Elderly

Published on: April 14, 2014

40.8K

科学分野:

  • 神経画像およびバイオマーカー研究;アルツハイマー病の病態生理

背景:

  • アルツハイマー病(AD)におけるアミロイド軌道の経験的決定は、縦断的アミロイド陽電子放出断層撮影(PET)データと高度な分析方法によって可能になっている。;アミロイド蓄積における生理学的上限を示唆する以前のモデルは、特にサンプリング反復局所近似(SILA)のようなノンパラメトリックアルゴリズムを使用した新しい分析では、一貫して支持されていない。

研究 の 目的:

  • 縦断的神経画像データを用いて、アミロイド蓄積における生理学的上限の有無を経験的に評価すること。;観察されたアミロイド軌道を、AD発症の確立されたモデルによって予測されたものと比較すること。

主な方法:

  • アルツハイマー病神経画像イニシアチブ(ADNI)およびJackモデルからのデータを用いたシミュレートされたアミロイド軌道。;最初のPETスキャン時の年齢、スキャン回数、スキャン間隔を含む、経験的に情報に基づいた確率的パラメータを組み込んだ。;蓄積率と上限効果における個体差を仮定し、公表された文献に基づいてアミロイド陽性発症年齢を推定した。

主要な成果:

  • ADNIデータへのSILAの実装により、アミロイド蓄積における生理学的上限の明らかな欠如が示唆された。;生理学的上限を組み込んだシミュレーションでは、ADNIデータで観察されたものとは質的に異なる軌道が生成された。;観察されたADNIデータには、上限に近づいていることを示すCentiloidsが高い状態での特徴的な密度増加が欠けていた。

結論:

  • SILAで分析された縦断的アミロイドPETデータは、アルツハイマー病におけるアミロイド蓄積の生理学的上限がないことを示唆している。;この所見は、臨床段階とベースラインのアミロイドレベルに基づいて上限を推測した以前の研究とは対照的である。;現在影響力のあるADバイオマーカー進化のモデルは、経験的なADNIデータと一致する軌道を生成しておらず、さらなるモデル改良の必要性を強調している。